Baidu
map

Cell子刊:为何抗癌药物无法渗透实体瘤?肿瘤内部压力大是重要原因

2016-05-16 佚名 生物谷

许多癌症治疗药物疗效不佳,其中一个原因就在于这些药物无法渗入实体瘤内部的高压环境。根据发表在国际学术期刊Biophysical Journal上的最新研究结果,透明质酸可导致肿瘤内部形成胶状液态压力环境,是导致癌症药物无法渗入的重要原因。   来自美国西雅图弗雷德哈金森癌症研究中心的Sunil Hingorani表示:"我们发现肿瘤内部的胶状液态环境是胰腺癌产生药物抵抗的主要机制

许多癌症治疗药物疗效不佳,其中一个原因就在于这些药物无法渗入实体瘤内部的高压环境。根据发表在国际学术期刊Biophysical Journal上的最新研究结果,透明质酸可导致肿瘤内部形成胶状液态压力环境,是导致癌症药物无法渗入的重要原因。
 
来自美国西雅图弗雷德哈金森癌症研究中心的Sunil Hingorani表示:"我们发现肿瘤内部的胶状液态环境是胰腺癌产生药物抵抗的主要机制。这同时意味着有必要重新审视之前认为无效的癌症治疗药物,搞清楚这些药物是否能够进入到肿瘤内部。除此之外,这种胶状液态环境可能在其它类型的肿瘤中也存在,因此应该针对该问题寻找新的药物运输方法。"
 
在进行该研究之前,研究人员提出假设,认为透明质酸产生的胶状液相环境是许多实体肿瘤内部出现高压状态的主要驱动因素。为了对这一观点进行验证,研究人员利用一种叫做压电式压力导管传感器(piezoelectric pressure catheter transducer)的设备捕获肿瘤内部的流动液体和胶样液体压力。他们将包含压力传感器的探针通过针头插入到胰腺癌小鼠模型的肿瘤内部,为了进行对比,他们还是用了经典的wick-in-needle技术进行了压力测量。
 
结果表明,用压电式压力导管传感器测量得到的压力数值要明显高于wick-in-needle技术,并且液相压力的增加与不同肿瘤模型内部透明质酸的含量增加呈现相关性。这就表明透明质酸依赖性的胶样液相压力环境在增加实体瘤内部压力方面发挥重要作用,这是之前研究从未发现过的。
 
研究人员接下来使用一种经过修饰的透明质酸酶治疗胰腺癌小鼠模型,帮助降解透明质酸。该治疗方法能够改变胶样液相环境,使血管得以重新形成,有助于解决药物运输问题,对于改善肿瘤病人的药物抵抗问题提供了重要帮助。
 
目前透明质酸酶联合治疗方法已经处于临床试验阶段,相信在不久的将来会成为癌症治疗的一种有效手段。
 
原始出处
 
Christopher C. DuFort1, Kathleen E. DelGiorno1, Markus A. Carlson1, Ryan J. Osgood3, Chunmei Zhao3.Interstitial Pressure in Pancreatic Ductal Adenocarcinoma Is Dominated by a Gel-Fluid Phase.Biophysical 2016

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1922280, encodeId=17df192228055, content=<a href='/topic/show?id=9aec36940eb' target=_blank style='color:#2F92EE;'>#压力大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36940, encryptionId=9aec36940eb, topicName=压力大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Fri Oct 14 09:50:00 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138163, encodeId=90e2138163b7, content=拜读,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 30 15:22:59 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814788, encodeId=49c71814e8811, content=<a href='/topic/show?id=d007960622e' target=_blank style='color:#2F92EE;'>#重要原因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96062, encryptionId=d007960622e, topicName=重要原因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Wed Aug 24 22:50:00 CST 2016, time=2016-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869375, encodeId=0b1418693e576, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Aug 14 05:50:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959632, encodeId=13fe19596324c, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Oct 19 22:50:00 CST 2016, time=2016-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308222, encodeId=212513082220f, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Wed May 18 11:50:00 CST 2016, time=2016-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314656, encodeId=6e5f131465608, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed May 18 11:50:00 CST 2016, time=2016-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86147, encodeId=f86b8614edf, content=肿瘤内部的胶状液态环境是胰腺癌产生药物抵抗的主要机制。这同时意味着有必要重新审视之前认为无效的癌症治疗药物,搞清楚这些药物是否能够进入到肿瘤内部。, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Tue May 17 16:58:00 CST 2016, time=2016-05-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1922280, encodeId=17df192228055, content=<a href='/topic/show?id=9aec36940eb' target=_blank style='color:#2F92EE;'>#压力大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36940, encryptionId=9aec36940eb, topicName=压力大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Fri Oct 14 09:50:00 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138163, encodeId=90e2138163b7, content=拜读,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 30 15:22:59 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814788, encodeId=49c71814e8811, content=<a href='/topic/show?id=d007960622e' target=_blank style='color:#2F92EE;'>#重要原因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96062, encryptionId=d007960622e, topicName=重要原因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Wed Aug 24 22:50:00 CST 2016, time=2016-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869375, encodeId=0b1418693e576, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Aug 14 05:50:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959632, encodeId=13fe19596324c, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Oct 19 22:50:00 CST 2016, time=2016-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308222, encodeId=212513082220f, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Wed May 18 11:50:00 CST 2016, time=2016-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314656, encodeId=6e5f131465608, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed May 18 11:50:00 CST 2016, time=2016-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86147, encodeId=f86b8614edf, content=肿瘤内部的胶状液态环境是胰腺癌产生药物抵抗的主要机制。这同时意味着有必要重新审视之前认为无效的癌症治疗药物,搞清楚这些药物是否能够进入到肿瘤内部。, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Tue May 17 16:58:00 CST 2016, time=2016-05-17, status=1, ipAttribution=)]
    2016-09-30 1e10c84am36(暂无匿称)

    拜读,好文

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1922280, encodeId=17df192228055, content=<a href='/topic/show?id=9aec36940eb' target=_blank style='color:#2F92EE;'>#压力大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36940, encryptionId=9aec36940eb, topicName=压力大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Fri Oct 14 09:50:00 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138163, encodeId=90e2138163b7, content=拜读,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 30 15:22:59 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814788, encodeId=49c71814e8811, content=<a href='/topic/show?id=d007960622e' target=_blank style='color:#2F92EE;'>#重要原因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96062, encryptionId=d007960622e, topicName=重要原因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Wed Aug 24 22:50:00 CST 2016, time=2016-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869375, encodeId=0b1418693e576, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Aug 14 05:50:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959632, encodeId=13fe19596324c, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Oct 19 22:50:00 CST 2016, time=2016-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308222, encodeId=212513082220f, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Wed May 18 11:50:00 CST 2016, time=2016-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314656, encodeId=6e5f131465608, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed May 18 11:50:00 CST 2016, time=2016-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86147, encodeId=f86b8614edf, content=肿瘤内部的胶状液态环境是胰腺癌产生药物抵抗的主要机制。这同时意味着有必要重新审视之前认为无效的癌症治疗药物,搞清楚这些药物是否能够进入到肿瘤内部。, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Tue May 17 16:58:00 CST 2016, time=2016-05-17, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1922280, encodeId=17df192228055, content=<a href='/topic/show?id=9aec36940eb' target=_blank style='color:#2F92EE;'>#压力大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36940, encryptionId=9aec36940eb, topicName=压力大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Fri Oct 14 09:50:00 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138163, encodeId=90e2138163b7, content=拜读,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 30 15:22:59 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814788, encodeId=49c71814e8811, content=<a href='/topic/show?id=d007960622e' target=_blank style='color:#2F92EE;'>#重要原因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96062, encryptionId=d007960622e, topicName=重要原因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Wed Aug 24 22:50:00 CST 2016, time=2016-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869375, encodeId=0b1418693e576, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Aug 14 05:50:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959632, encodeId=13fe19596324c, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Oct 19 22:50:00 CST 2016, time=2016-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308222, encodeId=212513082220f, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Wed May 18 11:50:00 CST 2016, time=2016-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314656, encodeId=6e5f131465608, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed May 18 11:50:00 CST 2016, time=2016-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86147, encodeId=f86b8614edf, content=肿瘤内部的胶状液态环境是胰腺癌产生药物抵抗的主要机制。这同时意味着有必要重新审视之前认为无效的癌症治疗药物,搞清楚这些药物是否能够进入到肿瘤内部。, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Tue May 17 16:58:00 CST 2016, time=2016-05-17, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1922280, encodeId=17df192228055, content=<a href='/topic/show?id=9aec36940eb' target=_blank style='color:#2F92EE;'>#压力大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36940, encryptionId=9aec36940eb, topicName=压力大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Fri Oct 14 09:50:00 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138163, encodeId=90e2138163b7, content=拜读,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 30 15:22:59 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814788, encodeId=49c71814e8811, content=<a href='/topic/show?id=d007960622e' target=_blank style='color:#2F92EE;'>#重要原因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96062, encryptionId=d007960622e, topicName=重要原因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Wed Aug 24 22:50:00 CST 2016, time=2016-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869375, encodeId=0b1418693e576, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Aug 14 05:50:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959632, encodeId=13fe19596324c, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Oct 19 22:50:00 CST 2016, time=2016-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308222, encodeId=212513082220f, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Wed May 18 11:50:00 CST 2016, time=2016-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314656, encodeId=6e5f131465608, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed May 18 11:50:00 CST 2016, time=2016-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86147, encodeId=f86b8614edf, content=肿瘤内部的胶状液态环境是胰腺癌产生药物抵抗的主要机制。这同时意味着有必要重新审视之前认为无效的癌症治疗药物,搞清楚这些药物是否能够进入到肿瘤内部。, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Tue May 17 16:58:00 CST 2016, time=2016-05-17, status=1, ipAttribution=)]
    2016-10-19 维他命
  6. [GetPortalCommentsPageByObjectIdResponse(id=1922280, encodeId=17df192228055, content=<a href='/topic/show?id=9aec36940eb' target=_blank style='color:#2F92EE;'>#压力大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36940, encryptionId=9aec36940eb, topicName=压力大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Fri Oct 14 09:50:00 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138163, encodeId=90e2138163b7, content=拜读,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 30 15:22:59 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814788, encodeId=49c71814e8811, content=<a href='/topic/show?id=d007960622e' target=_blank style='color:#2F92EE;'>#重要原因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96062, encryptionId=d007960622e, topicName=重要原因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Wed Aug 24 22:50:00 CST 2016, time=2016-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869375, encodeId=0b1418693e576, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Aug 14 05:50:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959632, encodeId=13fe19596324c, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Oct 19 22:50:00 CST 2016, time=2016-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308222, encodeId=212513082220f, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Wed May 18 11:50:00 CST 2016, time=2016-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314656, encodeId=6e5f131465608, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed May 18 11:50:00 CST 2016, time=2016-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86147, encodeId=f86b8614edf, content=肿瘤内部的胶状液态环境是胰腺癌产生药物抵抗的主要机制。这同时意味着有必要重新审视之前认为无效的癌症治疗药物,搞清楚这些药物是否能够进入到肿瘤内部。, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Tue May 17 16:58:00 CST 2016, time=2016-05-17, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1922280, encodeId=17df192228055, content=<a href='/topic/show?id=9aec36940eb' target=_blank style='color:#2F92EE;'>#压力大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36940, encryptionId=9aec36940eb, topicName=压力大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Fri Oct 14 09:50:00 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138163, encodeId=90e2138163b7, content=拜读,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 30 15:22:59 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814788, encodeId=49c71814e8811, content=<a href='/topic/show?id=d007960622e' target=_blank style='color:#2F92EE;'>#重要原因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96062, encryptionId=d007960622e, topicName=重要原因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Wed Aug 24 22:50:00 CST 2016, time=2016-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869375, encodeId=0b1418693e576, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Aug 14 05:50:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959632, encodeId=13fe19596324c, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Oct 19 22:50:00 CST 2016, time=2016-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308222, encodeId=212513082220f, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Wed May 18 11:50:00 CST 2016, time=2016-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314656, encodeId=6e5f131465608, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed May 18 11:50:00 CST 2016, time=2016-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86147, encodeId=f86b8614edf, content=肿瘤内部的胶状液态环境是胰腺癌产生药物抵抗的主要机制。这同时意味着有必要重新审视之前认为无效的癌症治疗药物,搞清楚这些药物是否能够进入到肿瘤内部。, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Tue May 17 16:58:00 CST 2016, time=2016-05-17, status=1, ipAttribution=)]
    2016-05-18 sunylz
  8. [GetPortalCommentsPageByObjectIdResponse(id=1922280, encodeId=17df192228055, content=<a href='/topic/show?id=9aec36940eb' target=_blank style='color:#2F92EE;'>#压力大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36940, encryptionId=9aec36940eb, topicName=压力大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Fri Oct 14 09:50:00 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138163, encodeId=90e2138163b7, content=拜读,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 30 15:22:59 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814788, encodeId=49c71814e8811, content=<a href='/topic/show?id=d007960622e' target=_blank style='color:#2F92EE;'>#重要原因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96062, encryptionId=d007960622e, topicName=重要原因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Wed Aug 24 22:50:00 CST 2016, time=2016-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869375, encodeId=0b1418693e576, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Aug 14 05:50:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959632, encodeId=13fe19596324c, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Oct 19 22:50:00 CST 2016, time=2016-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308222, encodeId=212513082220f, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Wed May 18 11:50:00 CST 2016, time=2016-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314656, encodeId=6e5f131465608, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed May 18 11:50:00 CST 2016, time=2016-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86147, encodeId=f86b8614edf, content=肿瘤内部的胶状液态环境是胰腺癌产生药物抵抗的主要机制。这同时意味着有必要重新审视之前认为无效的癌症治疗药物,搞清楚这些药物是否能够进入到肿瘤内部。, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Tue May 17 16:58:00 CST 2016, time=2016-05-17, status=1, ipAttribution=)]
    2016-05-17 jetleo

    肿瘤内部的胶状液态环境是胰腺癌产生药物抵抗的主要机制。这同时意味着有必要重新审视之前认为无效的癌症治疗药物,搞清楚这些药物是否能够进入到肿瘤内部。

    0

相关资讯

“可治百病的抗癌神药”是如何炼成的?

首先,这是一篇旧闻,不是新闻。 早在2010年8月23日,popular science网站上发布一篇新闻稿(Corey Binns.A PROTEIN KILLER COULD TREAT ALL CANCERS, AND POSSIBLY ALL ILLNESSES.Popular Science, Aug 23, 2010.)。在这篇新闻稿中提到美国一家Alnylam生物技术公司利用

Cell:微管结构助力抗癌药物开发

微管是直径仅有几纳米的微管蛋白的空心纤维,其可以形成活细胞的骨架并且在细胞分裂的过程中扮演着重要的角色;近日,刊登在Cell上的一篇报告中,来自加利福尼亚大学等处的研究者通过联合研究,将冷冻电镜技术同特殊的成像分析方法进行结合,成功地从原子视野对微管进行了观察,这对于理解微管在末端结合蛋白中的功能提供了一定帮助,而末端结合蛋白则可以调节微管的动态不稳定性。在有丝分裂期间微管可以拆解重新形成纺锤体

Sci Transl Med:基于免疫治疗的抗癌药物新消息

近日,纪念Sloan Kettering癌症中心和康奈尔医学院的研究人员们以一种特别的发行版本,在Science Translational Medicine杂志上发表了一篇综述。他们在此文章中描述了正在用于治疗多种不同癌症的免疫治疗药物的最新进展。这篇被作者三合一的综述聚焦于,目前研究的最新消息,临床试验信息,药物和其他关于免疫治疗的信息及有效提高激活人体自身抗病能力的研究进展。 多年

Environmental Microbiology:天然抗癌药物的真正起源

几十年来,科学家已经知道ET - 743是一种从海洋无脊椎动物中提取的称为被囊红树蝰的药物,该药物可以杀死癌细胞。在欧洲和美国临床试验中该药物已经批准用于病人。科学家们怀疑红树蝰被囊动物是一种海鞘类生物,实际上并不能生产ET - 743。但该药(曲贝替丁)的确切起源仍是一个谜。 通过使用先进的测序技术分析被囊类动物中微生物基因组,密歇根大学的研究人员能够分离ET- 743基因蓝图的制造者——

Nature Review:抗癌药物新靶标——mRNA

当今大多数抗癌药物作用机理是靶向肿瘤细胞的DNA或蛋白质,而加州大学伯克利分校的科学家们最近推出了一整套新的潜在目标:DNA和蛋白质之间的中介物质-mRNA。 mRNA在细胞核中转录形成,而后被编辑、穿梭到细胞质中蛋白质制造工厂——核糖体。大多数科学家认为这些分子除了有其独特的序列外,并没有作为药物针对目标的显著特点。但是,加州大学伯克利分校研究人员发现,mRNA中有一小部分编码一些与癌症有

陈扬超:以微核糖核酸(microRNA)为靶的抗癌药物研发

在生物谷举办的2014肿瘤转化医学研讨会上,来着香港中文大学生物医学院的陈扬超教授分享了以微核糖核酸(microRNA)为靶的抗癌药物研发。 陈教授现任香港中文大学深圳研究院基因调控与药物研发实验室主任,研究员,博士生导师;香港中文大学生物医学院博士生导师,助理教授。研究兴趣包括癌症生物学,非编码RNA,抗癌及抗病毒药物开发,主要利用慢病毒载体及RNA干扰等技术平台从事胃肠肿瘤分子生物学,基

Baidu
map
Baidu
map
Baidu
map